[1] Takei M, et al. Inhibitory activities of Gatifloxacin hydrochloride (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.Antimicrob Agents Chemother.?1998 Oct;42(10):2678-81. DOI:
10.1128/AAC.42.10.2678[2] Fukuda H, et al. Antibacterial activity of Gatifloxacin hydrochloride (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother.?1998 Aug;42(8):1917-22. DOI:
10.1128/AAC.42.8.1917[3] Yamada C, et al. Gatifloxacin hydrochloride?acutely?stimulates?insulin?secretion?and?chronically?suppresses?insulin?biosynthesis. Eur J Pharmacol.?2006 Dec 28;553(1-3):67-72. Epub 2006 Sep 28. DOI:
10.1016/j.ejphar.2006.09.043[4] Daw-Garza A, et al. In?vivo?therapeutic?effect?of?Gatifloxacin mesylate?on?BALB/c?mice?infected?with?Nocardia?brasiliensis.Antimicrob Agents Chemother.?2008 Apr;52(4):1549-50. DOI:
10.1128/AAC.00148-08